KredietR.T.The peritoneal membrane in chronic peritoneal dialysis.Kidney Int1999; 55: 341–56.
4.
DaviesS.J., PhillipsL., GriffithsA.M., RussellL.H., NaishP.F., RussellG.I.What really happens to people on long-term peritoneal dialysis?Kidney Int1998; 54: 2207–17.
5.
KredietR.T.The physiology of peritoneal solute transport and ultrafiltration. In: GokalR., KhannaR., KredietR.T., NolphK.D.A., eds. The Textbook of Peritoneal Dialysis. 2nd ed.Dordrecht: Kluwer Academic Publishers;2000: 135–72.
6.
ChurchillD.N., ThorpeK.E., NolphK.D.A., KeshaviahP.R., OreopoulosD.G., PagéD.Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients.J Am Soc Nephrol1998; 9: 1285–92.
7.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.Nephrol Dial Transplant1999; 14: 1541–9.
8.
MateijsenM.A., van der WalA.C., HendriksP.M., ZweersM.M., MulderJ., StruijkD.G.Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis.Perit Dial Int1999; 19: 517–25.
9.
DobbieJ.W.New concepts in molecular biology and ultrastructural pathology of the peritoneum: their significance for peritoneal dialysis.Am J Kidney Dis1990; 15: 97–109.
10.
CombetS., MiyataT., MoulinP., PouthierD., GoffinE., DevuystO.Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis.J Am Soc Nephrol2000; 11: 717–28.
11.
KubesP.Nitric oxide affects microvascular permeability in the intact and inflamed vasculature.Microcirculation1995; 2: 235–44.
12.
NeufeldG., CohenT., GengrinovitchS., PoltorakZ.Vascular endothelial growth factor (VEGF) and its receptors.FASEB J1999; 13: 9–22.
13.
NolphK.D.A., GhodsA., BrownP.A., MillerF., HarrisP.D., PyleK.Effects of nitroprusside on peritoneal mass transfer coefficients and microvascular physiology.ASAIO Trans1977; 23: 210–18.
14.
BreborowiczA., Wieczorowska-TobisK., KorybalskaK., PolubinskaA., RadkowskiM., OreopoulosD.G.The effect of a nitric oxide inhibitor (l-NAME) on peritoneal transport during dialysis in rats.Perit Dial Int1998; 18: 188–92.
CombetS., BalligandJ.L., LameireN., GoffinE., DevuystO.A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies.Kidney Int2000; 57: 332–8.
17.
CombetS., van LandschootM., MoulinP., PiechA., VerbavatzJ.M., GoffinE.Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis.J Am Soc Nephrol1999; 10: 2185–96.
18.
SzaboC.Pathophysiological roles of nitric oxide in inflammation. In: IgnarroL.J., ed. Nitric Oxide.San Diego: Academic Press;2000: 841–72.
19.
FerraraN.Role of vascular endothelial growth factor in the regulation of angiogenesis.Kidney Int1999; 56: 794–814.
ZweersM.M., de WaartD.R., SmitW., StruijkD.G., KredietR.T.Growth factors VEGF and TGF-beta1 in peritoneal dialysis.J Lab Clin Med1999; 134: 124–32.
22.
SelgasR., del PesoG., BajoM.A., CastroM.A., MolinaS., CirugedaA.Spontaneous VEGF production by cultured peritoneal mesothelial cells from patients on peritoneal dialysis.Perit Dial Int2000; 20: 798–801.
23.
InagiR., MiyataT., YamamotoT., SuzukiD., UrakamiK., SaitoA.Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett1999; 463: 260–4.
24.
FukumuraD., GohongiT., KadambiA., IzumiY., AngJ., YunC.O.Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability.Proc Natl Acad Sci U S A2001; 98: 2604–9.
25.
HoodJ.D., MeiningerC.J., ZicheM., GrangerH.J.VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.Am J Physiol1998; 274: H1054–8.
26.
TuderR.M., FlookB.E., VoelkelN.F.Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.J Clin Invest1995; 95: 1798–807.
27.
MiyataT., van Ypersele de StrihouC., KurokawaK., BaynesJ.W.Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications.Kidney Int1999; 55: 389–99.
28.
MiyataT., KurokawaK., van Ypersele de StrihouC.Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism.J Am Soc Nephrol2000; 11: 1744–52.
29.
RajD.S.C., ChoudhuryD., WelbourneT.C., LeviM.Advanced glycation end products: a nephrologist's perspective.Am J Kidney Dis2000; 35: 365–80.
30.
RubinJ., RustP., BrownP., PopovichR P., NolphK.D.A.A comparison of peritoneal transport in patients with psoriasis and uremia.Nephron1981; 29: 185–9.
31.
LauT., OwenW., YuY.M., NoviskiN., LyonsJ., ZurakowskiD.Arginine, citrulline, and nitric oxide metabolism in end-stage renal disease patients.J Clin Invest2000; 105: 1217–25.
32.
Muchaneta–KubaraE.C., Sayed–AhmedN., El NahasA.M.Subtotal nephrectomy: a mosaic of growth factors.Nephrol Dial Transplant1995; 10: 320–7.
33.
CombetS., FerrierM.L., van LandschootM., StoenoiuM., MoulinP., MiyataT.Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum.J Am Soc Nephrol2001; 12: 2146–57.
34.
UedaY., MiyataT., GoffinE., YoshinoA., InagiR., IzuharaY.Does removal of glucose lower the carbonyl stress of glucose containing peritoneal dialysis? Effect of dwell time on icodextrin and amino acid PD fluids.Kidney Int2000; 58: 2518–24.
35.
HobbsA.J., HiggsA., MoncadaS.Inhibition of nitric oxide synthase as a potential therapeutic target.Annu Rev Pharmacol Toxicol1999; 39: 191–220.
36.
GriffioenA.W., MolemaG.Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.Pharmacol Rev2000; 52: 237–68.
37.
FerraraN., AlitaloK.Clinical applications of angiogenic growth factors and their inhibitors.Nat Med1999; 5: 1359–64.
